These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2656051)

  • 1. Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy.
    Shetty HG; Fennerty AG; Routledge PA
    Clin Pharmacokinet; 1989 Apr; 16(4):238-53. PubMed ID: 2656051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.
    Palareti G; Legnani C
    Clin Pharmacokinet; 1996 Apr; 30(4):300-13. PubMed ID: 8983860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer.
    Camidge R; Reigner B; Cassidy J; Grange S; Abt M; Weidekamm E; Jodrell D
    J Clin Oncol; 2005 Jul; 23(21):4719-25. PubMed ID: 16034047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
    Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
    Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions.
    Wittkowsky AK
    Semin Vasc Med; 2003 Aug; 3(3):221-30. PubMed ID: 15199454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of warfarin and clinical implications.
    Keller C; Matzdorff AC; Kemkes-Matthes B
    Semin Thromb Hemost; 1999; 25(1):13-6. PubMed ID: 10327215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man.
    Levy G; Mager DE; Cheung WK; Jusko WJ
    J Pharm Sci; 2003 May; 92(5):985-94. PubMed ID: 12712418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.
    Frey R; Mück W; Kirschbaum N; Krätzschmar J; Weimann G; Wensing G
    J Clin Pharmacol; 2011 Jul; 51(7):1051-60. PubMed ID: 20801938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers.
    Uno T; Sugimoto K; Sugawara K; Tateishi T
    J Clin Pharm Ther; 2008 Feb; 33(1):67-73. PubMed ID: 18211619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target-based warfarin pharmacokinetics in the rat: the link with the anticoagulant effect.
    Thijssen HH; Janssen YP
    J Pharmacol Exp Ther; 1994 Aug; 270(2):554-8. PubMed ID: 8071848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers.
    Stangier J; Su CA; Hendriks MG; van Lier JJ; Sollie FA; Oosterhuis B; Jonkman JH
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1331-7. PubMed ID: 11185631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative study of the stability of oral anticoagulant treatments (warfarin vs acenocoumarol)].
    Amián A; Rodríguez JN; Muñiz R; Diéguez JC; Moreno MV; Quesada JA; Cañavate M; Fernández-Jurado A; Martino ML; Prados D
    Sangre (Barc); 1996 Feb; 41(1):9-11. PubMed ID: 8779047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
    Uno T; Sugimoto K; Sugawara K; Tateishi T
    Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why warfarin and heparin need to overlap when treating acute venous thromboembolism.
    Wittkowsky AK
    Dis Mon; 2005; 51(2-3):112-5. PubMed ID: 15900262
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.
    Holford NH
    Clin Pharmacokinet; 1986; 11(6):483-504. PubMed ID: 3542339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin?
    Zikria J; Ansell J
    Discov Med; 2009 Dec; 8(43):196-203. PubMed ID: 20040270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High intra- and inter-individual variability of plasma vitamin K concentrations in patients with atrial fibrillation under warfarin therapy.
    Kim YE; Woo HI; On YK; Kim JS; Lee SY
    Eur J Clin Nutr; 2015 Jun; 69(6):703-6. PubMed ID: 25828628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.
    Lilja JJ; Backman JT; Neuvonen PJ
    Br J Clin Pharmacol; 2005 Apr; 59(4):433-9. PubMed ID: 15801938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon.
    Haustein KO
    Semin Thromb Hemost; 1999; 25(1):5-11. PubMed ID: 10327214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.